BioPharma Services
BioPharma Services, a leading provider in the biopharmaceutical industry, is headquartered in the United States and operates across key regions including North America and Europe. Founded in 2004, the company has established itself as a trusted partner for pharmaceutical and biotechnology firms, offering a comprehensive range of services such as clinical trial management, regulatory consulting, and laboratory services. With a focus on delivering tailored solutions, BioPharma Services stands out for its commitment to quality and innovation, ensuring that clients navigate the complexities of drug development efficiently. The company has achieved significant milestones, including successful collaborations with major industry players, solidifying its position as a market leader. Through its expertise and dedication, BioPharma Services continues to contribute to advancements in healthcare and the biopharmaceutical landscape.
DitchCarbon Score
How does BioPharma Services's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BioPharma Services's score of 10 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BioPharma Services's reported carbon emissions
In 2023, BioPharma Services reported total carbon emissions of approximately 7,105,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions, primarily from mobile combustion, were about 5,600 kg CO2e, while Scope 2 emissions also totalled around 5,600 kg CO2e. The majority of their emissions, approximately 7,105,000,000 kg CO2e, fell under Scope 3, indicating significant indirect emissions associated with their value chain. Despite the substantial emissions figures, there are currently no disclosed reduction targets or climate pledges from BioPharma Services. This lack of specific commitments highlights an opportunity for the company to enhance its climate strategy and align with industry standards for sustainability. As the biopharmaceutical sector increasingly prioritises carbon neutrality, BioPharma Services may benefit from establishing clear reduction initiatives to mitigate its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 5,600 | 0,000 |
| Scope 2 | 5,600 | 0,000 |
| Scope 3 | 7,105,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BioPharma Services is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
